Efficacy of alpha-lipoic acid in patients with burning mouth syndrome compared to that of placebo or other interventions: a systematic review with meta-analyses

Jessica Christy¹, Salman Noorani¹, Frank Sy¹, Kamal Al-Eryani², Reyes Enciso³

¹Master of Science Program in Orofacial Pain and Oral Medicine, Herman Ostrow School of Dentistry of University of Southern California, Los Angeles, California, USA
²Clinical Dentistry, Herman Ostrow School of Dentistry of University of Southern California, Los Angeles, California, USA
³Department of Geriatrics, Special Needs and Behavioral Sciences, Herman Ostrow School of Dentistry of University of Southern California, Los Angeles, California, USA

Burning mouth syndrome (BMS) is a chronic oral disorder of unknown etiology which presents therapeutic challenges. Alpha-lipoic acid (ALA) has been studied as a potential treatment for BMS. The objective of this systematic review and meta-analysis was to evaluate the effectiveness of ALA compared to that of placebo or other interventions in individuals with BMS. Randomized controlled trials (RCT) using ALA to treat BMS were identified from MEDLINE, Cochrane Library, EMBASE, and Web of Science up to February 3, 2021. The assessment of the risk of bias in the included studies was based on the Cochrane guidelines. The primary outcome evaluated was the visual analog scale (VAS) pain intensity. ALA was compared with placebo, clonazepam, gabapentin, pregabalin, ALA plus gabapentin, capsaicin, Biotène®, and laser therapy. Altogether, 137 records were scanned for inclusion/exclusion, and nine RCTs (two unclear and seven at high risk of bias) were included in the qualitative and quantitative analyses, with a total of 594 patients with BMS included in this review. All studies reported an improvement in VAS pain scores ranging from -0.72 to -2.77. Meta-analysis results showed a non-significant reduction in pain intensity for ALA (P = 0.616) compared to that of placebo on a VAS of 0–10. Patients taking ALA were 1.923 times more likely to show an improvement in self-reported BMS symptoms (P = 0.031) than those in the placebo group. Clonazepam and pregabalin showed a significant VAS pain reduction of 4.08 and 4.68 (P < 0.001), respectively, compared to that with ALA. Although ALA intervention provided a non-significant improvement in the pain score and was more likely to produce a reduction in BMS symptoms, the evidence was of low quality. Further research is needed to establish clear guidelines for the use of ALA for BMS treatment.

Keywords: Alpha-lipoic acid; Burning Mouth Syndrome; Clonazepam; Meta-Analysis; Systematic Review.

INTRODUCTION

Burning mouth syndrome (BMS) is a chronic oral cavity disorder characterized by an intraoral burning sensation without any known dental or medical causes [1]. Predominant symptoms may be localized to the tongue and/or lips or may be more diffuse and involve the entire oral mucosa [1]. BMS is most prevalent in older adults, particularly women aged 50–70 years [2].
Comorbid conditions include xerostomia, dysgeusia, psychological conditions such as anxiety and depression, and nutritional deficiencies [3]. While BMS has classically been attributed to multiple factors, recent evidence hints at a link to peripheral small fiber neuropathy, trigeminal neuropathy, and/or centrally mediated pain, possibly related to dysfunctional dopaminergic neurons in the basal ganglia, which may result in dysesthesia, hyperalgesia, and allodynia [4]. BMS is a diagnosis of exclusion once other possible burning causes have been ruled out. These include vitamin/iron deficiencies, oral candidiasis, nerve trauma, tumors, and other immune-related diseases [1].

Alpha-lipoic acid (ALA) is a dietary supplement designated as an antioxidant that does not require prescription [5]. ALA contains sulfur and is produced in plants, animals, and humans [6]. It acts as a coenzyme in the Krebs cycle and as a cofactor in energy production in the cell [7]. Glutamate toxicity is a major contributor to pathological death in the nervous system. ALA protects against glutamate toxicity by reducing cellular levels of glutathione (GSH). When GSH is present at low levels in cells, oxidative stress, inflammation, and nerve damage occur, causing peripheral neuropathy [8]. ALA exerts its effect on the BMS by scavenging free radicals and may play a role in nerve repair [9]. Multiple randomized controlled trials (RCTs) have investigated its effects on reducing symptoms and providing relief to patients with BMS [10–12].

The exact etiology of BMS is unknown, but a likely cause is related to the reduction in the density of small fibers in the painful areas [13]. BMS is difficult to diagnose and is typically diagnosed by exclusion [14]. Currently, there are no comprehensive recognized guidelines for managing BMS, and we lack effective, proven treatment regimens as no treatment delivers a cure [14]. ALA has been shown in a meta-analysis [15] to have favorable outcomes for the treatment of diabetic neuropathy. Utilization of ALA to treat BMS could be beneficial owing to its similar etiologies [16]. ALA is readily found in food and can be purchased over the counter as a supplement or remedy. Evaluation of ALA as a possible treatment for BMS would be beneficial, especially for patients with pharmacophobia [17]. Pharmacophobia is the fear of taking medication and has been associated with the improper use of medications, refusal to take medication as prescribed, and relapse of a disorder or disease [17]. This systematic review was designed to analyze RCTs regarding the efficacy of ALA in the management of primary BMS, compared with placebo or other interventions in improving clinical outcomes.

**METHODS**

1. **Research question**

The guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) were followed [18], and the full protocol was registered with the international prospective registration system PROSPERO (CRD42021290489).

The research question understudy was as follows:

- **Study Type**: RCTs
- **Population**: adult patients with BMS
- **Intervention**: ALA
- **Comparison**: placebo intervention or other active interventions (ALA combined with vitamins, laser, and anticonvulsants)
- **Outcomes**: primary: pain intensity; secondary: BMS symptoms, pain frequency, quality of life outcomes, number of responders, and side effects and adverse events
- **Setting**: university medical/dental school

2. **Included/excluded studies**

Inclusion criteria: RCTs published in the English language on the efficacy of ALA compared with placebo or other active interventions.

Exclusion criteria: pilot studies, open-label studies, editorials, reviews, systematic reviews, meta-analyses, and practice guidelines.
3. Search strategies

In this systematic review, PubMed, EMBASE, Web of Science, and the Cochrane Library were searched up to February 3, 2021, using the search strategies described in Table 1.

4. Data collection and management

Three authors (S.N., J.C., and F.S.) screened all the results of the search strategy (Table 1), reviewed the title and abstract of all references, and decided on the relevance of the reference based on the inclusion/exclusion criteria. In the event of disagreement, the article was fully reviewed (PDF) by the three authors, and the final inclusion/exclusion was decided by consensus with another author (R.E.). The same three authors scanned the reference sections of all included studies (manual search), literature and systematic reviews, meta-analyses, and practice guidelines for further relevant records. The authors reviewed any new relevant references using the same inclusion and exclusion criteria. A fourth author (R.E.) made the final decision after reviewing the full-text if a disagreement arose.

Using a standardized form for data extraction, three authors (S.N., J.C., and F.S.) independently extracted the following from each eligible RCT: study design, funding, recruitment period, criteria for inclusion and exclusion, age and sex of participants in each group, details of the interventions, sample size per group, and outcomes reported in each study with results (means, standard deviations, standard error of the mean, etc.). A fourth reviewer (R.E.) curated and validated the data.

5. Risk of bias assessment

Three authors (S.N., J.C., and F.S.) independently analyzed the risk of bias for each study, which was then reviewed by the fourth author (R.E.). This procedural approach followed the methods described in the Cochrane handbook [19].

6. Statistical analyses

Only RCTs on the efficacy of ALA for the treatment of BMS compared with placebo or other interventions were included.

Barbosa et al. [20] reported the interquartile range (Q1, Q3) and the median (M). The review authors calculated the average = (Q1 + M + Q3) / 3 and standard deviation = (Q3 − Q1) / 1.35. Pain intensity was reported on a 0–10
or 0–100 visual analog scale (VAS). When more than one time point was reported, such as in Carbone et al. [5], for 2 and 4 months, the later measurement was used for the meta-analyses. For pain intensity, we reported the difference in the mean (DM) of the change in pain intensity from baseline with 95% confidence intervals (CI). We reported the risk ratios (RR) with 95% CI for the number of participants with improvement in pain or relief.

The Comprehensive Meta-Analysis v3 software (Biostat, Englewood, NJ, USA) was used in this study. Both Cochran's Q test [21] and the I² statistic [22] were used to test for heterogeneity. Effect estimates were combined with a random-effects model, if heterogeneity was present (Q-test P < 0.10), or with the fixed-effect model, if not present.

7. Subgroup and sensitivity analyses

Subgroup analyses for each comparison group (placebo, ALA + vitamins, Biotène, capsaicin, clonazepam, laser, and pregabalin) were conducted for pain intensity (VAS 0–10) to assess the effect of each intervention compared to that for ALA groups. Sensitivity analyses comparing the results, including only low risk of bias studies, were not conducted due to the small number of studies in each meta-analysis; for the same reason, a funnel plot could
### Table 2. Summary of included studies: Sample size, interventions, age, gender and study design

| Reference | Recruitment year, country, sample size | Interventions & sample size per group | Gender (M/F) | Mean age ± SD or median (range in yr or Interquartile Range) | Study design/overall risk of bias |
|-----------|--------------------------------------|--------------------------------------|--------------|------------------------------------------------------------|---------------------------------|
| Barbosa, et al. 2018 [20] | Brazil N = 15 | • ALA 600 mg/day (n = 5) • Laser (n = 10) | 6M/9F | Median 45.0 (Q25 = 40; Q75 = 52) | Not blinded RCT/HIGH |
| Carbone, et al. 2009 [5] | Italy N = 66 | • ALA 400 mg/day (n = 22) • ALA 400 mg + Vitamins C/PP/E/B6 • /B2/B1/B12/Folic Acid (n = 22) • Placebo (n = 22) | 54F/12M | 67.3 ± 11.9 | DBRPCT/UNCLEAR |
| Cavalcanti & da Silva, 2009 [24] | Brazil N = 38 | • Crossover • ALA 600 mg/day then Placebo (n = 19) • Placebo then ALA 600 mg/day (n = 19) | Mean 63.1 (range 36-78) | | DBRPCT Crossover /HIGH |
| Çinar, et al. 2015-17 | Turkey N = 75 | • ALA 600 mg [n = unknown] • Clonazepam 2 mg [n = unknown] • Pregabalin 150 mg [n = unknown] | ALA 15F Clonazepam: 16F Pregabalin: 17F (unknown number of males) | | Not blinded RCT/ HIGH Open label RCT |
| Femiano & Scully, 2002 [10] | Italy N = 60 | • ALA 600 mg/day X 2 mo (n = 30); • Placebo starch (n = 30) | 18M/42F | median 45 (22-68) | DBRPCT / UNCLEAR |
| López-D'alessandro & Escovich, 2003-2008 [26] | Argentina N = 120 | • ALA 600 mg/day x 2 mo [n = 20] • 300 mg/day Gabapentin x 2 mo. [n = 20] • ALA + gabapentin [n = 20] • Placebo starch [n = 60] | 26M/94F | mean 57.5 ± 14.1 median: 57 | DBRPCT/ UNCLEAR Double blinded RCT |
| López-Jornet, et al. 2007 | Spain N = 60 | • ALA 800 mg/day x 2 mo [n = 30] • Placebo [n = 30] | 56F/6M 2 dropouts | 64.37 ± 11.61 | DBRPCT/ HIGH |
| Marino, et. al. 2008 [27] | Italy N = 56 | • ALA 800 mg/day 400 mg 2xday [n = 14] • 250 mg capsaicin 3xday [n = 14] • Biotène®oral rinse 5xday [n = 14] • Control – boric acid 3xday [n = 14] | 10M/46F | 62 ± 9.8 | Single-blind open label RCT/ HIGH |
| Palacios-Sanchez, et al. 2014 | Spain N = 60 | • ALA 600 mg/day x 2mo. [n = 30] • Placebo [n = 30] | 5M/55F | 62.13years (Range 36-86) | DBRPCT/ HIGH |

Abbreviations: ALA, alpha-lipoic acid; DBRPCT, double-blinded randomized placebo-controlled trial; F, female gender; M, male gender; mo, month(s); N, total sample size; n, sample size per group; RCT, randomized controlled trial; SD, standard deviation.

not be created to assess publication bias.

### 8. Quality of the evidence (GRADE)

The review authors produced a summary of the findings for the quality of evidence assessment using the GRADE pro software developed by the working group named Grading of Recommendations Assessment, Development and Evaluation (GRADE) [23].

### RESULTS

#### 1. Results of the search

The search strategy initially yielded 227 references, which was reduced to 131 after removing duplicates. Three review authors independently assessed 131 records and reduced them to 18 relevant manuscripts based on the titles and abstracts. Of these, one record could not be retrieved and only nine RCTs were included. The main reasons for exclusion were review articles (n = 3), duplicates (n = 2), editorials (n = 2), and open trials (n = 1). Six additional records were identified by scanning the reference sections of the included studies (hand search); however, after a full review of the reports, six were excluded due not being an RCT (n = 2), no ALA intervention (n = 1), no BMS (n = 1), being a literature review (n = 1), and being a duplicate (n = 1). A summary of our results is presented in the PRISMA 2020 flowchart.
Table 3. Summary of inclusion criteria

| Reference | Inclusion Criteria |
|-----------|-------------------|
| Barbosa, et al. 2018 [20] | • Dx of BMS based on diagnostic criteria established by the IHS (sensation of burning or numbness in the oral mucosa that occurs for more than 2 h per day over more than 3 months in the absence of clinical alterations) [31] |
| Carbone, et al. 2009 [5] | • Presence of an isolated complaint of chronic pain in the oral mucosa with a normal clinical examination, and pain present for more than 4 months, which was continuous throughout all or part of the day, with no paroxysms and not following a nerve trajectory |
| Cavalcanti & da Silveira, 2009 [24] | • History of oral burning pain for more than 6 months and absence of oral finding |
| Çinar, et al. 2018 [25] | • Patients aged >18 years |
| Femiano & Scully, 2002 [10] | • Diagnosed with BMS from a history of constant burning discomfort in the anterior tongue, lower lip or hard palate, for more than two months, with no relevant drug or medical history |
| López-D’alessandro & Escovich, 2011 [26] | • Patients with BMS who have been treated at our service without responding to the applied treatment. • Idiopathic BMS of more than three months duration that wanted to participate voluntarily were included |
| Lopez-Jornet, et al. 2009 [11] | • Presentation of a clinical history of continuous symptomatology of oral burning or pain, daily or almost daily, during all or part of the day for more than 6 months evolution, without paroxysms, and independent of the nervous pathway; likewise, no clinical abnormality that would justify the symptomatology • had to present a normal blood analysis |
| Marino, et. al. 2010 [27] | • Symptoms of diffuse burning pain of the tongue and/or oral mucosa associated or unassociated with subjective oral dryness or loss or alteration of taste or sensation • Burning pain almost every day • Normal-looking mucosa in the region of burning • Absence of systemic disorders or laboratory alterations known to be associated with orofacial pain • Daily bilateral oral burning (or pain-like sensation) • Pain is unremitting for at least 4–6 months’ • Pain never worsens, but may be relieved, by eating and drinking pain seldom interfere with the sleep |
| Palacios-Sanchez, et al. 2015 [12] | • > 18 years of age • clinically diagnosed with BMS who reported a history of continuous oral burning pain for more than 4 months with no clinical signs that could justify the syndrome |

BMS, burning mouth syndrome; Dx, Diagnosis; IHS, International Headache Society; RCT, randomized controlled trial.

2. Included studies

A total of nine publications [5,10–12,20,24–27] comparing ALA to placebo or other active interventions (laser, vitamins, clonazepam, pregabalin, gabapentin, capsaicin, Biotène, ALA and vitamins, and ALA and gabapentin) used to treat BMS were eligible for qualitative analysis, as shown in Table 2.

1) Study design

This systematic review included five double-blind RCTs [5,10–12,26], one single-blind open-label RCT [27], one crossover double-blind RCT [24], and two unblinded RCTs [20,25].

2) Diagnosis of BMS

The population enrolled in the included RCTs was all adult patients (> 18 years) who had BMS. The diagnostic criteria for BMS for each study included in this review were clinical symptoms of burning or numbness of mouth (without any other pathological condition) for more than 2 months [10], 3 months [20,26], 4–6 months [5,12,27], or 6 months [11,24], with one study not being specific [25] (Table 3).

3) Demographics and setting

The participants ranged in ages from 22 to 86 years. The frequency of participants in each study ranged from 15 [20] to 120 [26]. In all the studies, women constituted the majority of the participants. All studies were conducted at university medical/dental schools in Brazil [20,24], Italy [5,10,27], Spain [11,12], Argentina [26], and Turkey [25].
at various doses and durations. The total daily dose was 400 mg [5], 600 mg [10,12,20,24–26], and 800 mg [11,27] (Table 2). The study duration varied from 1 month [20], 2 months [10,12,24,26], to 4 months [5,25,27]. One study analyzed the outcomes at both 1 and 2 months [11], and another at 2 and 4 months [5].

### Comparison groups varied from:

- The placebo group included matched placebo tablets composed of cellulose starch 100 mg [10–12,24,26]; boric acid (0.05 g) dissolved in distilled water (100 ml) as a mouth rinse[27]; or dicalcium phosphate, microcrystalline cellulose, hydroxypropylmethyl cellulose, silicon dioxide, vegetal magnesium stearate, shellac, and stearic acid [5].
- ALA 400 mg plus vitamins C, B3, E, B6, B2, B1, B12, and folic acid daily [5].
- Anticonvulsants included gabapentin 300 mg/day [26], pregabalin 150 mg/day [25], and clonazepam (2 mg/day) [25]. One study compared the 600 mg ALA group to 300 mg gabapentin combined with 600 mg ALA per day [26].
- Biotène® mouthwash five times a day [27].
- Capsaicin (250 mg) was emulsified in 50 ml of water, with no mention of the frequency of use [27].
- The laser was delivered as a weekly session of 10 s for 4 weeks [20].

5) Rescue medications

Three studies noted the use of co-interventions by patients [12,20,24]. In one trial, 45 patients were treated with antihypertensive agents, statins, anxiolytics, antiulcerogenic agents, antidiabetic agents, thyroid hormones, oral bisphosphonates, antidepressants, antipsychotics, nonsteroidal anti-inflammatory drugs, and muscle relaxants [20]. In another study, 19 patients had ongoing medications, including antidepressants with tranquilizers, antihypertensive medications, and hormonal repositioning [24]. A third study included participants taking antidepressants, anxiolytics, antihypertensives, thyroid medications, analgesics, antidiabetics, and antacids [12]. Multiple RCTs did not specify whether rescue medications were discontinued prior to the interventional therapy being administered to the study participants [5,10,11,25–27].

### 3. Risk of bias in included studies

Table 4 presents the assessment of the risk of bias. Two studies were assigned an unclear overall risk of bias [10,26] and six studies had a high overall risk of bias [5,11,12,20,24,25,27] (Fig. 2).

### 4. Adverse events

Several studies have reported on adverse events. These events included nausea and headaches, which led to
Fig. 2. Summary of risk of bias of eligible. RCT, randomized controlled trial.

Fig. 3. Pre- and post-VAS pain intensity reported in ALA groups (A), placebo groups (B), and other active interventions (C). Abbreviations: ALA, alpha-lipoic acid; Post-Tx, post-treatment; VAS, visual analog scale.

discontinuation of treatment for one patient [20]; strong headache caused discontinuation of treatment for one patient [24]; one patient abandoned the treatment in another study because of gastrointestinal upset [11]; and mild nausea and myalgia were also reported in the ALA group [25]. Studies reporting adverse events were
generally categorized as mild or minimal [10,11,25]. Four studies reported no adverse events [5,12,26,27]. Concerning other interventions excluding ALA, the authors reported dizziness (n = 4), transient diarrhea (n = 2), and myalgia (n = 2) with clonazepam; and increased appetite (n = 3), transient vertigo (n = 1), mild nausea (n = 1), and diarrhea (n = 1) in the pregabalin group [25].

(Fig. 3. continued)
5. Primary outcome: pain intensity

The primary outcome was pain intensity measured on a VAS 0–10, numerical rating scale (NRS) 0–10 [5,11, 20,25,27], or 0–100 VAS [24]. For the ALA groups (Fig. 3A), all studies reported a pain intensity improvement from baseline, ranging from -0.72 to -2.77 (0-10 scale). Barbosa et al. [20] reported the greatest difference at -2.77, and Cinar et al. [25] reported the least improvement in pain intensity at -0.72. However, the placebo group showed mixed results. Three studies [5,11,24] showed a decrease in pain intensity from baseline in the placebo groups, ranging from -1.25 to -3.8 units (Fig. 3B), and Marino et al. [27] showed an increase of 0.5. Other active interventions (clonazepam, pregabalin, laser, capsaicin, Biotène®, and ALA and vitamins) also showed a decrease in VAS from baseline, ranging from a decrease of -1.66 to -4.68. Pregabalin showed the most remarkable improvement in VAS at -4.68, while laser showed the least at -1.66 (Fig. 3C).
Efficacy of ALA in burning mouth syndrome

6. Meta-analyses results

1) ALA vs. placebo

Pre- and post-pain intensity (VAS 0–10) for the ALA groups compared to those of placebo were reported in three studies [5,11,27]. Pain intensity was not significantly different between the two groups (P = 0.616; Fig. 4A). Patients receiving ALA were 92.3% more likely to have an improvement in BMS self-reported symptoms than those in the placebo group (RR = 1.923; 95% CI = 1.060–3.488; P = 0.031; Fig. 4C) in five studies [10, 12,24,26,27].

2) ALA versus other active interventions

One study [25] reported significant improvements in pain intensity from baseline with clonazepam compared to that with placebo (DM = 3.360; 95% CI = 2.822–3.898; P < 0.001; Fig. 4B) in one arm and improvements with pregabalin compared to that with placebo in another arm of the study (DM = 3.960; 95% CI = 3.443–4.477; P < 0.001; Fig. 4B). There were no significant differences in the change in pain intensity with ALA and vitamins (P = 0.849), Biotēne® (P = 0.645), laser (P = 0.416), or capsaicin (P = 0.224) compared to that with placebo (Fig. 4B).

Patients receiving ALA and gabapentin were 83.3%
Table 5. GRADE assessment of the quality of the evidence

| Outcomes                                      | No of Participants (studies) | Quality of the evidence (GRADE) | Relative effect (95% CI) | Anticipated absolute effects |
|----------------------------------------------|-------------------------------|--------------------------------|--------------------------|-----------------------------|
| Change in pain intensity from baseline VAS0-10 | 144 (3 studies) 1-4 months   | ⊕⊕⊕⊝ LOW* due to risk of bias, inconsistency |  ---- ---- | The mean change in VAS pain intensity from baseline in the intervention groups was 0.613 units lower (3.007 lower to 1.782 higher) |
| Risk of any improvement in BMS symptoms     | 288 (5 studies) 2-4 months   | ⊕⊕⊕⊝ MODERATE* due to risk of bias | RR 1.923 (1.060 to 3.488) | 317 per 1000 293 more per 1000 (from 19 more to 789 more) |

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

* All studies at unclear/high risk of bias
† Minimal or no overlap of confidence intervals

Abbreviations: BMS, burning mouth syndrome; CI, confidence interval; GRADE, grading of recommendations, assessment, development, and evaluation; RR, risk ratio; VAS, visual analog scale.

more likely to have an improvement compared to those receiving ALA alone, although this result was not statistically significant (RR = 1.833; 95% CI = 0.842–3.991; P = 0.127; Fig. 4D).

7. Results for secondary outcomes reported in the included studies

1) ALA versus placebo

One study [5] reported a number of responders with an improvement of 50% in their symptoms of BMS from baseline to 8 and 16 weeks, measured using VAS scores of 0–10. There were no statistically significant differences in the number of responders between ALA and ALA combined with vitamins or placebo at 8 weeks (P = 0.126) and 16 weeks (P = 0.772) [5].

2) ALA versus laser

One RCT [20] reported an unstimulated salivary flow rate (ml/min) before and after the treatment. The increase in the ALA group of 0.1 ml/min from baseline was not statistically significant (P = 0.414). However, the laser therapy group showed a statistically significant improvement from the baseline (P = 0.034), with an increase of 0.2 ml/min [20]. The same study also reported TNF-α concentration levels before and after treatment, with a non-significant increase of + 8.0 pg/ml from baseline in the ALA group (P = 0.465) and a non-significant decrease of -1.8 in the laser group (P = 0.686) [20].

8. Quality of the evidence (GRADE)

In summary, due to an unclear or high risk of bias and the lack of overlap of confidence intervals (unexplained heterogeneity), the quality of the evidence was low (Table 5) for ALA compared to that for the placebo groups regarding the change in VAS pain from baseline (Fig. 4A), and moderate quality (Table 5) for the risk of any improvement in BMS symptoms (Fig. 4C). As shown for visual reference (Fig. 4B and 4D), other subgroup analyses included only one study; therefore, quality of the evidence (GRADE) could not be validated.

DISCUSSION

1. Summary of main findings and discussion

This systematic review investigated the effectiveness
of ALA as a therapeutic agent for the treatment of BMS at different dosages (400 mg, 600 mg, and 800 mg daily) versus placebo, other active interventions (clonazepam, pregabalin, gabapentin, laser, capsaicin, and Biotène®), and combination therapies (ALA plus gabapentin and ALA combined with vitamins).

1) ALA vs. placebo

Three studies [5,11,27] compared ALA versus placebo for BMS treatment, with two studies [5,27] showing a positive improvement in pain intensity from baseline in the ALA groups. However, the overall meta-analysis result, including these three studies, was insignificant (P = 0.616). The third study [11] had a high dropout rate, with only 39 of the 60 patients completing the study.

The risk of any improvement in symptoms with ALA was favorable in four of the studies versus placebo [10,12,26,27] and unfavorable to ALA in one study [24]. The pooled results showed that patients receiving ALA were 92% more likely to have an improvement in BMS symptoms (P = 0.031). These results are consistent with reviews by De Souza et al. [28], Liu et al. [14], and Phan et al. [29].

De Souza et al. [28] reported that 6 of 7 studies showed improvement in symptoms, although only four studies found ALA superior to placebo. Liu et al. [14] reported that five of six studies showed an improvement, with no significant differences in pain scores between ALA and placebo. Phan et al. [29] reported that ALA showed no significant difference in pain reduction from placebo (P = 0.713) and that ALA significantly improved patients’ symptoms in four studies (RR = 2.676; P < 0.001).

2) ALA vs. clonazepam

Çınar et al. (2018) [25] evaluated clonazepam for the treatment of BMS and reported a significant improvement in pain intensity compared to that with ALA (P < 0.001). Reyad et al. [30] also reviewed topical and systemic clonazepam for BMS compared with placebo and reported a significant reduction in VAS scores for patients treated with clonazepam. De Souza et al. [28] and Liu et al. [14] reported mixed results with systemic clonazepam and significantly superior results with topical clonazepam compared to that with placebo. Additional studies are required to confirm the efficacy of clonazepam.

3) ALA vs pregabalin/gabapentin

The use of pregabalin for BMS has shown inconclusive results. Çınar et al. (2018) [25] reported significant improvements in pain intensity with pregabalin compared to that with ALA (P < 0.001). López-D’aleashedandro and Escovitch [26] used topical gabapentin for BMS treatment and reported that patients receiving ALA plus gabapentin had an 83.3% increased chance of improvement compared to those receiving ALA alone, although this result was not statistically significant (P = 0.127). Reyad et al. [30] evaluated one case report using systemic pregabalin or gabapentin alone for the treatment of BMS and reported positive results for pregabalin, but not for gabapentin. Reyad et al. [30] also included a case series with mixed results that failed to confirm the efficacy of gabapentin. Further studies are required to evaluate pregabalin or gabapentin alone or in combination with ALA as a treatment modality for BMS.

4) ALA vs. Biotène/laser/capsaicin

Compared with ALA for the treatment of BMS, Biotène® (P = 0.645), laser (P = 0.416), and capsaicin (P = 0.224) showed no significant differences in pain intensity changes from baseline. Reyad et al. [30] reported positive effects of topical capsaicin and low-level laser therapy compared to that of placebo. Additional studies are needed owing to the limited availability of data.

2. Overall completeness and quality of the evidence

The search was conducted on four electronic databases (EMBASE, MEDLINE through PubMed, Web of Science, and Cochrane library) for articles published in the English language up to February 3, 2021. Three reviewers (S.N., J.C., and F.S.) independently assessed the risk of bias according to the guidelines of the
Cochrane Reviewers’ Handbook. Only RCTs comparing ALA with placebo or other active interventions were included in this review [5,10–12,20,24–27]. The risk of bias in the included articles was unclear or high. In addition to the lack of overlap in confidence intervals, the quality of the evidence was low.

3. Applicability of the evidence

The results of this study are applicable to people between 22 and 86 years of age of both sexes who suffer from BMS anywhere from 2 months to 6 months [5,10–12,20,24–27]. The RCTs were conducted in Brazil [20,24], Italy [5,10,27], Spain [11,12], Argentina [26], and Turkey [25], and all were performed in medical or dental university institutions.

4. Heterogeneity of the review

Heterogeneity was present in terms of the study design, as we included randomized clinical trials [20,25], double-blind, randomized placebo-controlled studies [5,11,12,26], one randomized placebo-controlled double-blind crossover study [24], one double-blind controlled study [10], and one single-blind randomized, prospective study [27]. The studies also had different treatment durations, ranging from 1 month [11,20], 2 months [10–12,24,26], to 4 months [5,25,27]. Placebo was used as a control in only six of the included studies [5,10–12,24,27]. Other comparison groups were laser [20], ALA in combination with vitamins [5], pregabalin [25], clonazepam [25], gabapentin [26], gabapentin in combination with ALA [26], capsaicin [27], and Biotène [27].

The dosage of ALA administered varied, with one study administering 400 mg [5], six studies utilizing a treatment dose of 600 mg [10,12,20,24–26], and two studies using an 800 mg dose [11,27]. Reporting of trial outcomes also varied among studies, with the most common being a change in VAS pain intensity (0–10 or 0–100) [5,11,12,20,24,25,27]. Other measurements of outcomes included unstimulated salivary flow rate, determination of TNF-alpha levels, global perceived effect, and changes in BMS symptomatology. How this heterogeneity might have affected the results of this systematic review remains unclear.

5. Implications for research and clinical practice

Areas that would be beneficial to evaluate in future research:

- Combination therapies such as topical ALA and topical clonazepam and gabapentin [26].
- Double-blind placebo-controlled randomized trials for the study of ALA with balanced sexes per group, large sample size, minimizing bias through computer-based randomization, and allocation concealment, ensuring that all patients are controlled for similar symptoms, medications, and underlying conditions.
- Further studies should include standardized outcomes (such as pain using the VAS scale 0–10), quality of life (such as improvement in daily activities and perception of improvement in symptoms), and unstimulated and stimulated salivary flow rates (to rule out symptomatic xerostomia).
- Studies with similar doses (ALA dosage of 600 mg or less owing to the high dropout rate and gastric side effects for doses higher than 600 mg).

The utilization of ALA in clinical practice may be beneficial as an adjunct to other therapies for BMS, such as gabapentin, clonazepam, or capsaicin. Further evaluation of this is warranted, as well as any allergies to sulfur.

6. Conclusions

Several therapies have been proposed for the treatment of BMS, but with a low grade of evidence. ALA is a naturally occurring agent that contains sulfur, is processed by humans, and prevents glutamate toxicity, which causes peripheral neuropathy. Our systematic review showed no significant improvement in pain intensity on the VAS and a significant improvement in symptoms in patients with BMS using ALA with a low grade of evidence. Due to small sample sizes, a limited number of studies, different doses of ALA, duration of the studies, and the presence
of heterogeneity, further studies with a larger sample size are required to assess its efficacy.

REFERENCES

1. Zakrzewska J, Buchanan JA. Burning mouth syndrome. BMJ Clin Evid 2016; 2016: 1301.
2. Thoppay JR, De Rossi SS, Ciarrocca KN. Burning mouth syndrome. Dent Clin North Am 2013; 57: 497-512.
3. Klein B, Thoppay JR, De Rossi SS, Ciarrocca K. Burning mouth syndrome. Dermatol Clin 2020; 38: 477-83.
4. Jääskeläinen SK. Pathophysiology of primary burning mouth syndrome. Clin Neurophysiol 2012; 123: 71-7.
5. Carbone M, Pentenero M, Carrozzo M, Ippolito A, Gandolfo S. Lack of efficacy of alpha-lipoic acid in burning mouth syndrome: a double-blind, randomized, placebo-controlled study. Eur J Pain 2009; 13: 492-6.
6. Salehi B, Berlay Yılmaz Y, Antika G, Boyunegmez Turner T, Fawzi Mahomoodally M, Lobine D, et al. Insights on the use of α-lipoic acid for therapeutic purposes. Biomolecules 2019; 9: 356.
7. Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med 1995; 19: 227-50.
8. Tirosh O, Sen CK, Roy S, Kobayashi MS, Packer L. Neuroprotective effects of α-lipoic acid and its positively charged amide analogue. Free Radic Biol Med 1999; 26: 1418-26.
9. Miziara I, Chagury A, Vargas C, Freitas L, Mahmoud A. Therapeutic options in idiopathic burning mouth syndrome: literature review. Int Arch Otorhinolaryngol 2015; 19: 86-9.
10. Femiano F, Scully C. Burning mouth syndrome (BMS): double blind controlled study of alpha-lipoic acid (thioctic acid) therapy. J Oral Pathol Med 2002; 31: 267-9.
11. López-Jornet P, Camacho-Alonso F, Leon-Espinosa S. Efficacy of alpha lipoic acid in burning mouth syndrome: a randomized, placebo-treatment study. J Oral Rehabil 2009; 36: 52-7.
12. Palacios-Sánchez B, Moreno-López LA, Cerero-lapiedra R, Llamas-martinez S, Espana-Gómez G. Alpha lipoic acid efficacy in burning mouth syndrome. A controlled clinical trial. Med Oral Patol Oral Cir Bucal 2015; 20: e435-40.
13. Bender SD. Burning mouth syndrome. Dent Clin North Am 2018; 62: 585-96.
14. Liu YF, Kim Y, Yoo T, Han P, Inman JC. Burning mouth syndrome: a systematic review of treatments. Oral Dis 2018; 24: 325-34.
15. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: a meta-analysis. Diabet Med 2004; 21: 114-21.
16. Papanas N, Ziegler D, Papanas N, Ziegler D. Efficacy of α-lipoic acid in diabetic neuropathy. Expert Opin Pharmacother 2014; 15: 2721-31.
17. Petelinšek A, Lauri Korajlija A. Predictors of pharaco-phobia. Health Psychol Res 2020; 8: 8853.
18. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.
19. Higgins J, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. [Internet]. 2011. Available from: www.cochrane-handbook.org
20. Barbosa NG, Gonzaga AKG, de Sena Fernandes LL, da Fonseca AG, Queiroz SIML, Lemos TMAM, et al. Evaluation of laser therapy and alpha-lipoic acid for the treatment of burning mouth syndrome: a randomized clinical trial. Lasers Med Sci 2018; 33: 1255-62.
21. Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 10: 101-29.
22. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.
23. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011; 64: 383-94.
24. Cavalcanti DR, da Silva FR. Alpha lipoic acid in burning mouth syndrome - a randomized double-blind placebo-controlled trial. J Oral Pathol Med 2009; 38: 254-61.
25. Çınar SL, Kartal D, Pergel T, Borlu M. Effectiveness and safety of clonazepam, pregabalin, and alpha lipoic acid for the treatment of burning mouth syndrome. Erciyes Med J 2018; 40: 35-8.
26. López-D’alessandro E, Escovich L. Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: a randomized, double-blind, placebo controlled trial. Med Oral Patol Oral Cir Bucal 2011; 16: e635-40.
27. Marino R, Torretta S, Capaccio P, Pignataro I, Spadari F. Different therapeutic strategies for burning mouth syndrome: preliminary data. J Oral Pathol Med 2010; 39: 611-6.
28. de Souza IF, Mârmore BC, Rados PV, Visioli F. Treatment modalities for burning mouth syndrome: a systematic review. Clin Oral Investig 2018; 22: 1893-905.
29. Phan Y, Yeh R, Colmenar G, Suarez-durall P, Enciso R. Effect of medications, dietary supplements and psychosocial interventions in burning mouth syndrome patients: a systematic review with meta-analyses. Open J Dent Oral Med 2017; 5: 31-46.
30. Reyad AA, Mishriky R, Girgis E. Pharmacological and non-pharmacological management of burning mouth syndrome: a systematic review. Dent Med Probl 2020; 57: 295-304.
31. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 2013; 33: 629-808.